TITLE:
Treatment of Wegener's Granulomatosis With Cyclophosphamide

CONDITION:
Vasculitis

INTERVENTION:
cyclophosphamide

SUMMARY:

      The purpose of this protocol is to continue to treat patients with Wegener's granulomatosis
      who have already entered the study, and to treat new patients. The investigators will
      attempt to correlate the clinical response with specific immunosuppressive effects of drug
      administration. The investigators are accumulating data on the optimal duration and side
      effects of therapy.
    

DETAILED DESCRIPTION:

      The purpose of the protocol is to continue to treat patients with Wegener's granulomatosis
      who have already entered the study, and to treat new patients. The investigators will
      attempt to correlate the clinical response with specific immunosuppressive effects of drug
      administration. The investigators are accumulating data on the optimal duration and side
      effects of therapy.

      Age Range: greater than 1 year
    

ELIGIBILITY:
Gender: All
Age: N/A to N/A
Criteria:

        Patients greater than 1 year of age with the clinical and pathological diagnosis of WG
        whose illness presents a risk of permanent disability or death. Examples of processes that
        impart risk of permanent disability or death include: peripheral and central nervous
        system disease, cardiac involvement, glomerulonephritis, and vascular comprise of
        gastrointestinal organs.

        No women who are pregnant or intend to become pregnant.

        No patients who have known malignancies.

        Patients must be HIV negative.
      
